## IDEXX (IDXX) — filings-driven deep dive (business + financials + key events) ### 1) What IDEXX is (and how it makes money) IDEXX develops/manufactures/distributes products and provides services primarily for companion animal veterinary diagnostics and software, plus smaller Water and Livestock/Poultry/Dairy (LPD) businesses, and a small “Other” segment (OPTI Medical + out-licensing). ["develop, manufacture, and distribute"](0000874716-25-000037|0) ["operate primarily through three business segments"](0000874716-25-000037|0) **Segment architecture (as disclosed):** - **Companion Animal Group (CAG):** In-clinic diagnostics (VetLab instruments + consumables), rapid assays (SNAP), reference lab services, plus practice management software & diagnostic imaging/PACS. ["Companion Animal Group (“CAG”)"](0000874716-25-000037|0) - **Water:** microbiology testing (e.g., Colilert/Enterolert/Legiolert) + trays/sealers/instruments. ["Water quality products (“Water”)"](0000874716-25-000037|0) - **LPD:** livestock/poultry diagnostics + dairy antibiotic residue tests. ["Livestock, Poultry and Dairy (“LPD”)"](0000874716-25-000037|0) A core economics point IDEXX highlights: **recurring diagnostics revenue** (consumables + reference lab + services) is structurally higher margin than instrument placements, so mix matters. ["Recurring Diagnostic Revenue"](0000874716-24-000057|0) --- ### 2) FY2024 scale and mix (GAAP segment revenue, USD thousands) | Segment (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | CAG revenue | 3,574,044 ["CAG segment revenue"](0000874716-25-000037|0) | 3,352,356 ["CAG segment revenue"](0000874716-25-000037|0) | 3,058,793 ["CAG segment revenue"](0000874716-25-000037|0) | | Water revenue | 185,112 ["Water segment revenue"](0000874716-25-000037|0) | 168,149 ["Water segment revenue"](0000874716-25-000037|0) | 155,720 ["Water segment revenue"](0000874716-25-000037|0) | | LPD revenue | 122,060 ["LPD segment revenue"](0000874716-25-000037|0) | 121,659 ["LPD segment revenue"](0000874716-25-000037|0) | 122,607 ["LPD segment revenue"](0000874716-25-000037|0) | | Other revenue | 16,288 ["Other segment revenue"](0000874716-25-000037|0) | 18,789 ["Other segment revenue"](0000874716-25-000037|0) | 30,204 ["Other segment revenue"](0000874716-25-000037|0) | | **Total revenue** | **3,897,504** ["Total revenue"](0000874716-25-000037|0) | **3,660,953** ["Total revenue"](0000874716-25-000037|0) | **3,367,324** ["Total revenue"](0000874716-25-000037|0) | **What this implies (computed):** - CAG was ~91.7% of FY2024 revenue (computed = 3,574,044 / 3,897,504). ["CAG segment revenue"](0000874716-25-000037|0) ["Total revenue"](0000874716-25-000037|0) --- ### 3) Inside CAG: “where” growth comes from (CAG category revenue, USD thousands) This disclosure is useful because it separates the **recurring engine** (consumables, reference lab, software subscriptions) from **capital instruments** (more cyclical/mix-sensitive). | CAG revenue breakdown (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | **CAG Diagnostics recurring revenue** | 3,129,492 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | 2,935,425 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | 2,660,280 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | | └ IDEXX VetLab consumables | 1,303,250 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | 1,188,261 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | 1,057,236 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | | └ Rapid assay products | 359,754 ["Rapid assay products"](0000874716-25-000037|0) | 344,494 ["Rapid assay products"](0000874716-25-000037|0) | 313,667 ["Rapid assay products"](0000874716-25-000037|0) | | └ Reference lab & consulting | 1,336,121 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | 1,278,617 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | 1,178,113 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | | └ Diagnostics services & accessories | 130,367 ["services and accessories"](0000874716-25-000037|0) | 124,053 ["services and accessories"](0000874716-25-000037|0) | 111,264 ["services and accessories"](0000874716-25-000037|0) | | **CAG Diagnostics capital – instruments** | 131,928 ["capital - instruments"](0000874716-25-000037|0) | 137,603 ["capital - instruments"](0000874716-25-000037|0) | 147,326 ["capital - instruments"](0000874716-25-000037|0) | | **Vet software/services & imaging systems** | 312,624 ["Veterinary software"](0000874716-25-000037|0) | 279,328 ["Veterinary software"](0000874716-25-000037|0) | 251,187 ["Veterinary software"](0000874716-25-000037|0) | | └ Recurring revenue | 250,359 ["Recurring revenue"](0000874716-25-000037|0) | 214,597 ["Recurring revenue"](0000874716-25-000037|0) | 180,973 ["Recurring revenue"](0000874716-25-000037|0) | | └ Systems & hardware | 62,265 ["Systems and hardware"](0000874716-25-000037|0) | 64,731 ["Systems and hardware"](0000874716-25-000037|0) | 70,214 ["Systems and hardware"](0000874716-25-000037|0) | **Analyst read:** IDEXX’s “quality” is largely in the **recurring layers** (consumables + reference lab + software subscriptions). Instruments are strategically important (they seed the installed base) but can dilute margin in periods of high placements—IDEXX explicitly discusses mix effects in quarterly MD&A. ["business mix impact"](0000874716-25-000165|0) --- ### 4) Profitability + cash generation (cash flow statement view; USD thousands) | Cash flow / capital deployment (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net income | 887,867 ["Net income"](0000874716-25-000037|0) | 845,042 ["Net income"](0000874716-25-000037|0) | 679,089 ["Net income"](0000874716-25-000037|0) | | Net cash from operations | 929,001 ["Net cash provided"](0000874716-25-000037|0) | 906,510 ["Net cash provided"](0000874716-25-000037|0) | 542,984 ["Net cash provided"](0000874716-25-000037|0) | | Capex (PP&E purchases) | (120,922) ["Purchases of property"](0000874716-25-000037|0) | (133,631) ["Purchases of property"](0000874716-25-000037|0) | (148,838) ["Purchases of property"](0000874716-25-000037|0) | | Business acquisitions (net of cash acquired) | (76,694) ["Acquisitions of businesses"](0000874716-25-000037|0) | — ["Acquisitions of businesses"](0000874716-25-000037|0) | (11,512) ["Acquisitions of businesses"](0000874716-25-000037|0) | | Share repurchases | (837,034) ["Repurchases of common"](0000874716-25-000037|0) | (71,920) ["Repurchases of common"](0000874716-25-000037|0) | (819,711) ["Repurchases of common"](0000874716-25-000037|0) | | Ending cash & equivalents | 288,266 ["Cash and cash equivalents"](0000874716-25-000037|0) | 453,932 ["Cash and cash equivalents"](0000874716-25-000037|0) | 112,546 ["Cash and cash equivalents"](0000874716-25-000037|0) | **Analyst read:** IDEXX is a classic “high recurring revenue + high buyback intensity” model. In FY2024, buybacks (~$837m) were the largest single use of financing cash. ["Repurchases of common stock"](0000874716-25-000037|0) --- ### 5) Balance sheet snapshot (USD thousands) | (USD ‘000) | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & equivalents | 288,266 ["Cash and cash equivalents"](0000874716-25-000037|0) | 453,932 ["Cash and cash equivalents"](0000874716-25-000037|0) | | Total assets | 3,293,443 ["TOTAL ASSETS"](0000874716-25-000037|0) | 3,259,925 ["TOTAL ASSETS"](0000874716-25-000037|0) | | Credit facility (current) | 250,000 ["Credit facility"](0000874716-25-000037|0) | 250,000 ["Credit facility"](0000874716-25-000037|0) | | Long-term debt (net of current portion) | 449,786 ["Long-term debt"](0000874716-25-000037|0) | 622,883 ["Long-term debt"](0000874716-25-000037|0) | | Total stockholders’ equity | 1,595,313 ["Total IDEXX"](0000874716-25-000037|0) | 1,484,530 ["Total IDEXX"](0000874716-25-000037|0) | --- ### 6) Latest quarterly operating cadence (Q3 2025 10‑Q) **Total company income statement (Q3 2025 vs Q3 2024, USD thousands):** | (USD ‘000) | Q3 2025 | Q3 2024 | |---|---:|---:| | Revenue | 1,105,239 ["Revenues"](0000874716-25-000165|0) | 975,543 ["Revenues"](0000874716-25-000165|0) | | Gross margin (computed) | 61.8% (computed) ["Gross profit"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | 61.1% (computed) ["Gross profit"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | | Operating income | 354,846 ["Income from operations"](0000874716-25-000165|0) | 303,892 ["Income from operations"](0000874716-25-000165|0) | | Operating margin (computed) | 32.1% (computed) ["Income from operations"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | 31.2% (computed) ["Income from operations"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | **Management’s stated growth drivers in the quarter (high-level):** - Revenue growth driven mainly by **CAG Diagnostics recurring revenue** (volume + realized price), supported by new business and test-menu expansion, with some macro/sector headwinds. ["growth in CAG Diagnostics recurring revenue"](0000874716-25-000165|0) - Instrument revenue gains tied to placements of **IDEXX inVue Dx Analyzer**. ["placements of our new IDEXX inVue Dx"](0000874716-25-000165|0) --- ### 7) Event / governance filings: CEO transition (January 2026 8‑K) IDEXX filed an 8‑K dated **January 11, 2026** announcing a CEO transition plan: current CEO Jonathan (Jay) Mazelsky intends to step down as CEO effective **May 12, 2026**, transition to Executive Chair, and retire from the Company/Board after the 2027 annual meeting; Michael (Mike) Erickson, PhD, will become CEO on the transition date. ["Date of earliest event"](0001104659-26-003103|0) ["effective as of May 12, 2026"](0001104659-26-003103|0) ["Michael (Mike) Erickson"](0001104659-26-003103|0) **Disclosed CEO compensation terms (incoming CEO):** - Base salary $1,000,000; target bonus 120% of base. ["annualized base salary of $1,000,000"](0001104659-26-003103|0) ["target of 120%"](0001104659-26-003103|0) - 2026 target LTIP equity award grant date value **≥ $7.8m** (50% options / 50% PRSUs). ["not less than $7.8 million"](0001104659-26-003103|0) ["stock options (50%)"](0001104659-26-003103|0) **Why this matters analytically:** it reduces key-person uncertainty by formalizing a timeline and role transition, but it also introduces **execution risk** around leadership change during ongoing product/platform initiatives (e.g., point-of-care menu expansion + software workflow buildout). ["transition to the role of Executive Chair"](0001104659-26-003103|0) --- ### 8) Selected disclosure-driven risks to keep in view From the filings, several “watch items” stand out as recurring, business-model-relevant risk themes: - **Customer concentration risk via industry consolidation** (large corporate hospital owners/buying consortiums pressuring pricing and potentially shifting purchasing/testing). ["veterinary services industry"](0000874716-24-000057|0) - **Cybersecurity and IT disruption risk** (acknowledges past incidents; warns of potential operational and reputational impacts). ["experienced cybersecurity attacks"](0000874716-25-000037|0) - **Climate and extreme weather operational risk** (physical + transition risks affecting operations/supply chain/customers). ["disrupted by climate change"](0000874716-24-000057|0) - **Legal contingency example (royalty underpayment litigation)** with a large accrual update (important for “one-time” noise vs. underlying earnings power). ["increased our previously established accrual"](0000874716-25-000037|0) ["to $89.0 million"](0000874716-25-000037|0) --- If you want, I can extend this into a **full thesis-style write-up** (moat, competitive positioning, key KPIs to track like installed base/utilization, and a filings-based timeline of major acquisitions/financing/repurchase authorizations) using additional 10‑Q / 8‑K exhibits and the proxy once it’s filed.

## IDEXX (IDXX) — filings-driven deep dive (business + financials + key events) ### 1) What IDEXX is (and how it makes money) IDEXX develops/manufactures/distributes products and provides services primarily for companion animal veterinary diagnostics and software, plus smaller Water and Livestock/Poultry/Dairy (LPD) businesses, and a small “Other” segment (OPTI Medical + out-licensing). ["develop, manufacture, and distribute"](0000874716-25-000037|0) ["operate primarily through three business segments"](0000874716-25-000037|0) **Segment architecture (as disclosed):** - **Companion Animal Group (CAG):** In-clinic diagnostics (VetLab instruments + consumables), rapid assays (SNAP), reference lab services, plus practice management software & diagnostic imaging/PACS. ["Companion Animal Group (“CAG”)"](0000874716-25-000037|0) - **Water:** microbiology testing (e.g., Colilert/Enterolert/Legiolert) + trays/sealers/instruments. ["Water quality products (“Water”)"](0000874716-25-000037|0) - **LPD:** livestock/poultry diagnostics + dairy antibiotic residue tests. ["Livestock, Poultry and Dairy (“LPD”)"](0000874716-25-000037|0) A core economics point IDEXX highlights: **recurring diagnostics revenue** (consumables + reference lab + services) is structurally higher margin than instrument placements, so mix matters. ["Recurring Diagnostic Revenue"](0000874716-24-000057|0) --- ### 2) FY2024 scale and mix (GAAP segment revenue, USD thousands) | Segment (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | CAG revenue | 3,574,044 ["CAG segment revenue"](0000874716-25-000037|0) | 3,352,356 ["CAG segment revenue"](0000874716-25-000037|0) | 3,058,793 ["CAG segment revenue"](0000874716-25-000037|0) | | Water revenue | 185,112 ["Water segment revenue"](0000874716-25-000037|0) | 168,149 ["Water segment revenue"](0000874716-25-000037|0) | 155,720 ["Water segment revenue"](0000874716-25-000037|0) | | LPD revenue | 122,060 ["LPD segment revenue"](0000874716-25-000037|0) | 121,659 ["LPD segment revenue"](0000874716-25-000037|0) | 122,607 ["LPD segment revenue"](0000874716-25-000037|0) | | Other revenue | 16,288 ["Other segment revenue"](0000874716-25-000037|0) | 18,789 ["Other segment revenue"](0000874716-25-000037|0) | 30,204 ["Other segment revenue"](0000874716-25-000037|0) | | **Total revenue** | **3,897,504** ["Total revenue"](0000874716-25-000037|0) | **3,660,953** ["Total revenue"](0000874716-25-000037|0) | **3,367,324** ["Total revenue"](0000874716-25-000037|0) | **What this implies (computed):** - CAG was ~91.7% of FY2024 revenue (computed = 3,574,044 / 3,897,504). ["CAG segment revenue"](0000874716-25-000037|0) ["Total revenue"](0000874716-25-000037|0) --- ### 3) Inside CAG: “where” growth comes from (CAG category revenue, USD thousands) This disclosure is useful because it separates the **recurring engine** (consumables, reference lab, software subscriptions) from **capital instruments** (more cyclical/mix-sensitive). | CAG revenue breakdown (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | **CAG Diagnostics recurring revenue** | 3,129,492 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | 2,935,425 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | 2,660,280 ["CAG Diagnostics recurring revenue"](0000874716-25-000037|0) | | └ IDEXX VetLab consumables | 1,303,250 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | 1,188,261 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | 1,057,236 ["IDEXX VetLab consumables"](0000874716-25-000037|0) | | └ Rapid assay products | 359,754 ["Rapid assay products"](0000874716-25-000037|0) | 344,494 ["Rapid assay products"](0000874716-25-000037|0) | 313,667 ["Rapid assay products"](0000874716-25-000037|0) | | └ Reference lab & consulting | 1,336,121 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | 1,278,617 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | 1,178,113 ["Reference laboratory diagnostic"](0000874716-25-000037|0) | | └ Diagnostics services & accessories | 130,367 ["services and accessories"](0000874716-25-000037|0) | 124,053 ["services and accessories"](0000874716-25-000037|0) | 111,264 ["services and accessories"](0000874716-25-000037|0) | | **CAG Diagnostics capital – instruments** | 131,928 ["capital - instruments"](0000874716-25-000037|0) | 137,603 ["capital - instruments"](0000874716-25-000037|0) | 147,326 ["capital - instruments"](0000874716-25-000037|0) | | **Vet software/services & imaging systems** | 312,624 ["Veterinary software"](0000874716-25-000037|0) | 279,328 ["Veterinary software"](0000874716-25-000037|0) | 251,187 ["Veterinary software"](0000874716-25-000037|0) | | └ Recurring revenue | 250,359 ["Recurring revenue"](0000874716-25-000037|0) | 214,597 ["Recurring revenue"](0000874716-25-000037|0) | 180,973 ["Recurring revenue"](0000874716-25-000037|0) | | └ Systems & hardware | 62,265 ["Systems and hardware"](0000874716-25-000037|0) | 64,731 ["Systems and hardware"](0000874716-25-000037|0) | 70,214 ["Systems and hardware"](0000874716-25-000037|0) | **Analyst read:** IDEXX’s “quality” is largely in the **recurring layers** (consumables + reference lab + software subscriptions). Instruments are strategically important (they seed the installed base) but can dilute margin in periods of high placements—IDEXX explicitly discusses mix effects in quarterly MD&A. ["business mix impact"](0000874716-25-000165|0) --- ### 4) Profitability + cash generation (cash flow statement view; USD thousands) | Cash flow / capital deployment (USD ‘000) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net income | 887,867 ["Net income"](0000874716-25-000037|0) | 845,042 ["Net income"](0000874716-25-000037|0) | 679,089 ["Net income"](0000874716-25-000037|0) | | Net cash from operations | 929,001 ["Net cash provided"](0000874716-25-000037|0) | 906,510 ["Net cash provided"](0000874716-25-000037|0) | 542,984 ["Net cash provided"](0000874716-25-000037|0) | | Capex (PP&E purchases) | (120,922) ["Purchases of property"](0000874716-25-000037|0) | (133,631) ["Purchases of property"](0000874716-25-000037|0) | (148,838) ["Purchases of property"](0000874716-25-000037|0) | | Business acquisitions (net of cash acquired) | (76,694) ["Acquisitions of businesses"](0000874716-25-000037|0) | — ["Acquisitions of businesses"](0000874716-25-000037|0) | (11,512) ["Acquisitions of businesses"](0000874716-25-000037|0) | | Share repurchases | (837,034) ["Repurchases of common"](0000874716-25-000037|0) | (71,920) ["Repurchases of common"](0000874716-25-000037|0) | (819,711) ["Repurchases of common"](0000874716-25-000037|0) | | Ending cash & equivalents | 288,266 ["Cash and cash equivalents"](0000874716-25-000037|0) | 453,932 ["Cash and cash equivalents"](0000874716-25-000037|0) | 112,546 ["Cash and cash equivalents"](0000874716-25-000037|0) | **Analyst read:** IDEXX is a classic “high recurring revenue + high buyback intensity” model. In FY2024, buybacks (~$837m) were the largest single use of financing cash. ["Repurchases of common stock"](0000874716-25-000037|0) --- ### 5) Balance sheet snapshot (USD thousands) | (USD ‘000) | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & equivalents | 288,266 ["Cash and cash equivalents"](0000874716-25-000037|0) | 453,932 ["Cash and cash equivalents"](0000874716-25-000037|0) | | Total assets | 3,293,443 ["TOTAL ASSETS"](0000874716-25-000037|0) | 3,259,925 ["TOTAL ASSETS"](0000874716-25-000037|0) | | Credit facility (current) | 250,000 ["Credit facility"](0000874716-25-000037|0) | 250,000 ["Credit facility"](0000874716-25-000037|0) | | Long-term debt (net of current portion) | 449,786 ["Long-term debt"](0000874716-25-000037|0) | 622,883 ["Long-term debt"](0000874716-25-000037|0) | | Total stockholders’ equity | 1,595,313 ["Total IDEXX"](0000874716-25-000037|0) | 1,484,530 ["Total IDEXX"](0000874716-25-000037|0) | --- ### 6) Latest quarterly operating cadence (Q3 2025 10‑Q) **Total company income statement (Q3 2025 vs Q3 2024, USD thousands):** | (USD ‘000) | Q3 2025 | Q3 2024 | |---|---:|---:| | Revenue | 1,105,239 ["Revenues"](0000874716-25-000165|0) | 975,543 ["Revenues"](0000874716-25-000165|0) | | Gross margin (computed) | 61.8% (computed) ["Gross profit"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | 61.1% (computed) ["Gross profit"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | | Operating income | 354,846 ["Income from operations"](0000874716-25-000165|0) | 303,892 ["Income from operations"](0000874716-25-000165|0) | | Operating margin (computed) | 32.1% (computed) ["Income from operations"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | 31.2% (computed) ["Income from operations"](0000874716-25-000165|0) ["Revenues"](0000874716-25-000165|0) | **Management’s stated growth drivers in the quarter (high-level):** - Revenue growth driven mainly by **CAG Diagnostics recurring revenue** (volume + realized price), supported by new business and test-menu expansion, with some macro/sector headwinds. ["growth in CAG Diagnostics recurring revenue"](0000874716-25-000165|0) - Instrument revenue gains tied to placements of **IDEXX inVue Dx Analyzer**. ["placements of our new IDEXX inVue Dx"](0000874716-25-000165|0) --- ### 7) Event / governance filings: CEO transition (January 2026 8‑K) IDEXX filed an 8‑K dated **January 11, 2026** announcing a CEO transition plan: current CEO Jonathan (Jay) Mazelsky intends to step down as CEO effective **May 12, 2026**, transition to Executive Chair, and retire from the Company/Board after the 2027 annual meeting; Michael (Mike) Erickson, PhD, will become CEO on the transition date. ["Date of earliest event"](0001104659-26-003103|0) ["effective as of May 12, 2026"](0001104659-26-003103|0) ["Michael (Mike) Erickson"](0001104659-26-003103|0) **Disclosed CEO compensation terms (incoming CEO):** - Base salary $1,000,000; target bonus 120% of base. ["annualized base salary of $1,000,000"](0001104659-26-003103|0) ["target of 120%"](0001104659-26-003103|0) - 2026 target LTIP equity award grant date value **≥ $7.8m** (50% options / 50% PRSUs). ["not less than $7.8 million"](0001104659-26-003103|0) ["stock options (50%)"](0001104659-26-003103|0) **Why this matters analytically:** it reduces key-person uncertainty by formalizing a timeline and role transition, but it also introduces **execution risk** around leadership change during ongoing product/platform initiatives (e.g., point-of-care menu expansion + software workflow buildout). ["transition to the role of Executive Chair"](0001104659-26-003103|0) --- ### 8) Selected disclosure-driven risks to keep in view From the filings, several “watch items” stand out as recurring, business-model-relevant risk themes: - **Customer concentration risk via industry consolidation** (large corporate hospital owners/buying consortiums pressuring pricing and potentially shifting purchasing/testing). ["veterinary services industry"](0000874716-24-000057|0) - **Cybersecurity and IT disruption risk** (acknowledges past incidents; warns of potential operational and reputational impacts). ["experienced cybersecurity attacks"](0000874716-25-000037|0) - **Climate and extreme weather operational risk** (physical + transition risks affecting operations/supply chain/customers). ["disrupted by climate change"](0000874716-24-000057|0) - **Legal contingency example (royalty underpayment litigation)** with a large accrual update (important for “one-time” noise vs. underlying earnings power). ["increased our previously established accrual"](0000874716-25-000037|0) ["to $89.0 million"](0000874716-25-000037|0) --- If you want, I can extend this into a **full thesis-style write-up** (moat, competitive positioning, key KPIs to track like installed base/utilization, and a filings-based timeline of major acquisitions/financing/repurchase authorizations) using additional 10‑Q / 8‑K exhibits and the proxy once it’s filed.